Mid-Year Report — TROUTMAN STRATEGIES for BRANDED PHARMACEUTICAL ASSOCIATION (2007)

Firm

TROUTMAN STRATEGIES

Client

BRANDED PHARMACEUTICAL ASSOCIATION

Income

$60,000

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 2900, Food and Drug Administration Amendments Act of 2007 S 1082, Prescription Drug User Fee Amendments of 2007 Monitor legislative impacting prescription drugs

Lobbyist	Covered position, as disclosed
PATRICK ANDERSON	N/A
ROBERT LEEBERN	N/A
BENJAMIN CRAIG NOBLE	N/A
LAURA QUATTLEBAUM	N/A

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 2900 (110th)

Budget/Appropriations BUD

HR 3161 and S 1859 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Act of 2008

Lobbyist	Covered position, as disclosed
PATRICK ANDERSON	N/A
ROBERT LEEBERN	N/A
BENJAMIN CRAIG NOBLE	N/A
LAURA QUATTLEBAUM	N/A

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 3161 (110th)

Pharmacy PHA

Seek legislative and regulatory support for Desi drugs

Lobbyist	Covered position, as disclosed
PATRICK ANDERSON	N/A
ROBERT LEEBERN	N/A
BENJAMIN CRAIG NOBLE	N/A
LAURA QUATTLEBAUM	N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.